news
Novartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
List view / Grid view
Novartis
article
Key takeaways from the AACR Meeting 2022
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.
news
UK Government launches Pandemic Preparedness Partnership group
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
article
How labs become AI ready with advanced informatics infrastructures
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
article
TCR therapy – an attractive alternative to CAR T
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
news
Chemical reactions database updates to improve R&D information exchange
The newest version of the Unified Data Model (UDM) project has been released, allowing R&D scientists to access information on compound synthesis and testing.
news
Malaria vaccine targets PMIF
A new malaria vaccine targets the protein PMIF, which is crucial in the life cycle of malaria parasites...
news
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer...
news
Kymab appoints Dr Sonia Quaratino as Chief Medical Officer
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
news
Genmab appoints Judith Klimovsky as Chief Development Officer
The biotechnology company Genmab announced today the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer.
news
Big pharma establishes new industry standards group
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
news
Novartis expands immuno-oncology pipeline with Surface Oncology alliance
11 January 2016 | By Victoria White
The agreement gives Novartis access to four preclinical programmes that target regulatory T-cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment...
article
Enabling new targets by integrated lead discovery
Progress in the understanding of disease mechanisms provides new opportunities to discover molecules that modulate disease. To capitalise on these opportunities, successful lead discovery strategies need to build on insights into how a cellular phenotype or a target contributes to disease biology. Recent advances in induced pluripotent stem cells (iPSCs),…
news
XOMA licenses anti-TGFb antibody programme to Novartis
2 October 2015 | By Victoria White
Elevated levels of TGFb may drive the progression of advanced metastatic cancer. As such, it has become an attractive target for cancer drug development...
news
European Antibody Congress 2015 comes to Basel
18 August 2015 | By The European Antibody Congress
The European Antibody Congress takes place 9-11 November 2015 at the Congress Centre, Basel...